Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric Cancer.

导出 OA

翻译打印收藏纠错

第一作者： Ryan H,Moy

第一单位： Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York, USA.

作者： Ryan H,Moy ^[1] ; Gustavo,Dos Santos Fernandes ^[1] ; Philip,Jonsson ^[2] ; Joanne F,Chou ^[3] ; Azfar,Basunia ^[4] ; Geoffrey Y,Ku ^[3] ; Sree B,Chalasani ^[2] ; Michelle S,Boyar ^[1] ; Zoe,Goldberg ^[1] ; Avni M,Desai ^[1] ; Amelia,Gabler ^[1] ; Michael F,Berger ^[1] ; Laura H,Tang ^[1] ; Jaclyn F,Hechtman ^[2] ; David P,Kelsen ^[4] ; Mark,Schattner ^[5] ; David H,Ilson ^[5] ; David B,Solit ^[5] ; Barry S,Taylor ^[1] ; Nikolaus,Schultz ^[1] ; Marinela,Capanu ^[1] ; Yelena Y,Janjigian ^[1]

作者单位： Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York, USA. ^[1] Marie-Josée & Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA. ^[2] Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA. ^[3] Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA. ^[4] Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA. ^[5]

关键词 Angiogenesis Esophagogastric cancer Regorafenib Targeted therapy